
Opinion|Videos|April 4, 2025
EMPOWER-Lung 1: Baseline Characteristics and Modern Treatment Considerations in NSCLC
Author(s)Eric K. Singhi, M.D., Ben Creelan, M.D.
Panelists discuss how, at their practices, histology, staging and ECOG performance status guide treatment decisions for advanced non-small cell lung cancer (NSCLC). Compared with EMPOWER-Lung 1, these factors remain crucial. Key biomarkers, such as PD-L1 expression, influence PD-1 inhibitor efficacy. In 2025, treatment options are more personalized with emerging therapies.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- How does histology, staging and ECOG performance status play into treatment considerations at your practice today, and how do these factors compare to the baseline characteristics of this study?
- What other biomarkers, if any, are important in determining the efficacy of PD-1 inhibitors like cemiplimab before initiating therapy, both in NSCLC and for other indications?
- Overall, how does this patient population compare with those treated in 2025 with immune checkpoint inhibitors or other first-line treatment options for advanced NSCLC?
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
1,700 sites closed, 77,000 fewer children received PEPFAR-supported treatment after PEPFAR disruption | IAS 2026
2
Payers lean on step therapy, formulary exclusions as IRA reshapes Part D benefit design
3
Redemplo cuts triglycerides, pancreatitis risk in severe hypertriglyceridemia
4
Step therapy requirements drive up time, costs in DME patients | ASRS 2026
5


























